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Abstract
Purpose Dairy products are rich in nutrients that positively
influence bone health and hence fracture risk, and have there-
fore been recommended and used for fracture prevention. To
help decision makers to efficiently allocate scare resources, it
is further important to assess the public health and economic
impact of any health intervention. In recent years, several
studies have been conducted to estimate the public health
and/or economic impact of dairy products but no overview
is currently available. This article aims therefore to summarize
evidence and review articles that estimated the public health
and/or economic impact of vitamin D-fortified dairy products
for fracture prevention.
Methods A literature review was conducted using PubMed to
identify original studies that assessed the public health and/or
economic impact of dairy products (or of calcium/vitamin D
supplementation) for fracture prevention up to January 15,
2017.
Results Seven articles were identified. Different strategies
were used by the authors to model the economic/public health
impact of dairy products. The four studies assessing the public
health impact of dairy products revealed a substantial benefit
in terms of fracture prevented, life years, disability-adjusted
life years and/or quality-adjusted life years gained. Studies
assessing the cost-effectiveness revealed that the use of dairy
products is generally cost-effective in the general population
aged above 70 years, and from the age of 60 years in popula-
tions at high risk of fractures.
Conclusion This systematic review suggests that the use of
dairy products could substantially reduce the burden of oste-
oporotic fractures and seem to be an economically beneficial
strategy.
Keywords Cost-effectiveness . Dairy products . Fractures .
Nutrition . Osteoporosis . Public health
Introduction
Calcium and vitamin D are essential to protect bone and
prevent osteoporotic fractures. A recent Cochrane review
suggests that there is high-quality evidence that vitamin D
plus calcium result in small and significant reductions in
the risk of hip fracture (16%), in the risk of vertebral frac-
ture (14%) and in the risk of any non-vertebral fracture (11%)
(1). International experts groups have reviewed the benefits of
calcium and vitamin D for fracture prevention and provided
recommendations for an optimal intake (2–6). All these arti-
cles recommend the concomitant use of calcium and vitamin
D supplementation in elderly especially in patients at high risk
of calcium and vitamin D insufficiency. It is generally recom-
mended to intake 800 IU/day of vitamin D and 1000 mg of
calcium per day (3).
There is high prevalence of vitamin D and calcium in-
sufficiency in elderly men and women (7, 8). In a study
conducted in nine European countries, the prevalence of vita-
min D inadequacy was estimated at 80.9 and 44.5% when
considering cut-offs of 75 and 50 nmol/L in elderly women
aged over 80 years (8). The adequate intake of calcium is also
far from optimal, with about only 20% of women consuming
* Mickael Hiligsmann
m.hiligsmann@maastrichtuniversity.nl
1 Department of Health Services Research, CAPHRI Care and Public
Health Research Institute, Maastricht University, P.O. Box 616, 6200
MD Maastricht, the Netherlands
2 Department of Public Health, Epidemiology and Health Economics,
University of Liège, Liège, Belgium
Arch Osteoporos  (2017) 12:57 
DOI 10.1007/s11657-017-0352-1
≥1000 mg of calcium per day (7, 9). It is therefore needed to
adequately supplement elderly patients with calcium and vi-
tamin D especially those at high risk of vitamin D and calcium
insufficiency and those taking osteoporosis medications (4,
10). Dairy products are rich in nutrients that are essential for
good bone health, including calcium, vitamin D, protein, potas-
sium, phosphorus, and other micronutrients and macronutrients
(11) that are known to positively influence bone and muscle
homeostasis, hence fracture risk. The European guidance for
the diagnosis and management of osteoporosis (12) therefore
recommends dietary sources of calcium as the preferred option.
As calcium is mainly provided in dairies, calcium- and vitamin
D-fortified dairy products (yogurt, milk) providing 400 mg of
calcium and 200 IU of vitamin D per portion are valuable
options (12).
To help decision makers in making health policy about
preventive nutrition programs, it is important to assess the
public health and economic impact of the intake of vitamin
D-fortified dairy products. Economic evaluations are nowa-
days increasingly used by decision makers when making de-
cisions about healthcare resource allocation. Given the in-
creasing awareness of the benefits of calcium and vitamin D
to prevent bone loss and the need for economic assessment,
several studies have thus been conducted to assess the public
health and/or economic impact of dairy products for fracture
prevention in recent years. To our knowledge, no overview of
these studies is currently available. Synthesizing and reviewing
this literature is important to inform decision makers about the
potential public health and economic impact of dairy products.
The aim of this study was therefore to summarize evidence and
review articles that estimated the public health and/or economic
impact of vitamin D-fortified dairy products for fracture
prevention.
Methods
We conducted a review in PubMed to identify published
studies that assessed the public health and/or economic
impact of dairy products for fracture prevention. We com-
bined different key terms (using MESH terms when possi-
ble) related to osteoporosis (i.e. osteoporosis, bone frac-
ture), with economic terms (i.e. cost-benefit, cost-effec-
tiveness, economic, cost, public health) and with nutrition
terms (i.e. dairy products, nutrition, calcium and vitamin D
supplementation). All original articles published in English
or French until January 15, 2017, were included. We only
included original research that assessed the public health
and/or the economic impact of fortified dairy products for
bone prevention loss. Studies assessing calcium and vita-
min D supplementation were also included, while studies
looking at vitamin D supplementation only were excluded.
Abstract and title screening was initially performed by one
investigator, followed by a full-text screening. References of
identified articles were searched for additional articles; the op-
tion Bsee all related^ from PubMed was also used and further
completed by authors’ knowledge of the published literature.
Data were collected on study first author, title, country, pub-
lication year, method, outcome, interventions, and main results.
Given the heterogeneity between studies, a narrative reviewwas
used to report the findings.
Public health impact
To measure the public health impact of dairy products, different
outcomes could be used including the number of fractures
prevented, the number of life years saved, the number of
quality-adjusted life years (QALY) or disability-adjusted life
years (DALY) gained or in money (referred as cost-of-illness
study). QALY is an attractive outcome measure combining
quality of life (morbidity) and quantity of life (mortality) in a
singlemetric and is also the outcome used in cost-utility analysis
(13). DALY is another measure of disease burden, expressed as
the number of years lost due to disability or early death.
Economic impact
To assess the economic impact of an intervention, econom-
ic evaluations are conducted with the aim to compare the
costs and outcomes of two or more health interventions
(13). We distinguish between a cost-effectiveness analysis
(CEA) where the outcome is expressed in natural units
(such as the number of fractures prevented) and a cost-
utility analysis (CUA) where QALY is used as outcome.
The latter is often preferred since it allows comparisons
between different interventions and diseases. The results
of an economic evaluation (CUA or CEA) are expressed
in terms of incremental cost-effectiveness ratio (ICER)
which is defined as the difference in cost between the in-
tervention and the comparator divided by their differences
in outcomes. An ICER represents the additional cost of the
intervention per unit of effect (e.g. cost per fractures
prevented, or cost per QALY gained). If the ICER is lower
than a certain threshold representing the maximum deci-
sion makers that are willing to pay for a unit of effect, the
intervention is considered cost-effective. In CEA, no
thresholds are generally available; for CUA, there is no
consensus on the cost per QALY gained that represents
good value for money. Thresholds in the range of
€30,000–€45,000 are the most commonly used for defin-
ing cost-effectiveness. The World Health Organization has
suggested a value of three times the gross domestic product
(GDP) per capita as the DALY value to be used as cost-
effectiveness threshold in developed countries. Borgström
et al. (14) have suggested a threshold for QALY equal to
two times the GDP per capital for industrialized countries.
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This threshold has been used for defining fracture risk
thresholds in several countries (15, 16).
Results
Study characteristics
A total of 125 articles were identified through the PubMed
search, of which a total of 7 articles met our inclusion criteria
(17–23) (see flow chart on Fig. 1). The study characteristics
are included in Table 1.
Five of these studies (17, 18, 21–23) assessed the public
health and/economic impact of dairy products (also called
vitamin D-fortified dairy products, vitamin D and calcium
food fortification, vitamin D-rich dairy products) while two
studies (19, 20) assessed the impact of calcium and vitamin D
supplementation without mentioning the specific use of dairy
products. Four studies assessed the public health impact of
dairy products in terms of costs, number of fractures
prevented, life years gained, DALY gained or QALY gained
(17, 21–23) and all studies except the study of Lotters assessed
the cost-effectiveness of dairy products (or calcium and vita-
min D supplementation). Four studies estimated the cost per
QALY gained of dairy products (17, 19–21), one assessed the
cost per fracture prevented and cost per life year gained (17),
and one study used a benefit-cost ratio comparing costs and
fractures prevented (23).
Three studies were conducted in Belgium (17, 18, 20), one in
France (21), one in Germany (23), one in Norway (19) and one
study included three countries (i.e. Sweden, the Netherlands and
France) (22). All studies used a model to simulate the public
health or economic impact. Most studies (17, 18, 20, 21) used a
previously validated Markov microsimulation model that has
frequently been used to assess the cost-effectiveness of osteo-
porosis interventions (24).
Different strategies were used by the authors to model the
public health impact of dairy products. Ethgen et al. (17)
assessed the public health impact of appropriate daily intake
during the remaining lifetime of a cohort, while Hiligsmann
et al. (21) assumed an appropriate intake for 1 year and assessed
the lifetime implications of this 1-year appropriate intake. In
Sandmann et al. (23), the effect of a voluntary food fortification
programme was assessed (assuming an 82% adherence level to
the programme). Lotters et al. (22) assessed the potential impact
of increasing dairy foods consumption in people with an inad-
equate calcium intake. Hagen et al. (19) assessed the impact of
cardiovascular effects on the cost-effectiveness of calcium and
vitamin D supplementation.
The effect of dairy products on the risk of fractures was
derived from systematic reviews. Three studies (17, 18, 20) used
the results of a literature search of articles describing the efficacy
of vitamin D in combination with calcium in terms of fracture
risk reduction (20). The three most recent studies (19, 21, 23)
used the effect of calcium and vitamin D supplementation on
fracture risk from a Cochrane review (1).
Public health impact
Four studies assessed the public health impact of dairy products
(18, 21–23) (see Table 2).
First, Lotters et al. (22) estimated that the number of hip
fractures that may potentially be prevented each year with
additional dairy products was 2023 in France, 455 in
Records identified in PubMed and screened
(n=125)
Search: (dairy product[MeSH Terms] OR  nutrition[Title/Abstract]) OR calcium vitamin 
D[Title/Abstract]) AND (cost benefit[MeSH Terms]) OR economic[Title/Abstract]) OR public 
health[Title/Abstract]) OR cost-effectiveness[Title/Abstract]) AND (osteoporosis[MeSH 
Terms]) OR bone fracture[MeSH Terms])
Full-text articles assessed 
for eligibility
(n=10) Full-text articles excluded 
(n=4).






Fig. 1 Literature search flow
chart
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Sweden and 132 in the Netherlands. The yearly number of
DALY lost was estimated at 6263 for France, 1246 for
Sweden, and 374 for The Netherlands. The corresponding
total costs that might potentially be avoided were estimated
at €129 million, €34 million, and €6 million, in these coun-
tries, respectively.
Second, Ethgen et al. (17) estimated the projected health
and economic impact of the recommended dairy daily intake
versus the absence of appropriate intake in Belgium. The au-
thors estimated that 30,376 fractures and 6605 life years could
be saved for an appropriate dairy intake over the remaining
lifetime of all women aged over 50 years. In men, the number
of fracture avoided and life years gained were estimated at
16,105 and 6144 respectively.
Third, Sandmann et al. (23) estimated that the implemen-
tation of a vitamin D and calcium food fortification pro-
gramme would lead to annual net cost savings of €315 million
and the prevention of 36,705 fractures in the German female
population aged 65 years and older.
Fourth, in the general French population aged over
60 years, Hiligsmann et al. estimated the lifetime health im-
pacts of the recommended intake of dairy products in the
general French population for 1 year (2015) (21). The recom-
mended intake of dairy would reduce the total lifetime number
of fractures by 64,932, of which 46,472 and 18,460 would
occur in women and men, respectively. In particular, 19,500
hip fractures could be prevented. Dairy products would also
result in 32,569 QALYs and 29,169 life years gained.
Table 3 Economic impact of the use of dairy products for fracture prevention
Study Cost-effectiveness
Ethgen (2015) Using cost per fracture avoided as outcome, dairy products at a yearly cost of €350 are cost-effective from 70 years
on in the general population and from 60 years on in patients at increased risk of osteoporotic fractures
Hiligsmann (2015) The cost per QALY gained of vitamin D/calcium supplementation was estimated at €40,578 and €23,477 in women
and men aged 60 years, respectively. These values were €7912 and €10,250 at the age of 70 years and vitamin D
and calcium supplementation was cost-saving at the age of 80 years
Ethgen (2016) The daily intake of two yogurts is cost-effective above 80 years in the general population and above 70 years
in women at increased risk of fractures
Sandmann (2016) Vitamin D and calcium food fortification programme is cost-saving (annual net cost savings and better outcomes
resulting from fracture prevention)
Hagen (2016) The cost-effectiveness of calcium and vitamin D supplementation was estimated at €14,453 per QALY gained
for the average 65-year-old Norwegian women assuming no cardiovascular effects
Hiligsmann (2017) The cost per QALY gained of appropriate dairy intake (2 dairy products per day) was estimated at €58,244
in the general French population aged over 60 years and fall below a threshold of €30,000 per QALY
gained in women over 70 years and in men over 80 years
QALY quality-adjusted life years
Table 2 Public health impact of
the use of dairy products for
fracture prevention
Study Public health impact
Lotters (2013) - Yearly number of hip fractures prevented: 2023 (FR), 455 (SW), 132 (NL)
- Yearly number of DALYs gained: 6263 (FR), 1246 (SW), 374 (NL)
- Yearly total costs avoided: €129 million (FR), €34 (SW), €6 (NL).
Ethgen (2015) Lifetime impact of recommended intake of dairy products over the remaining lifetime:
- Number of fractures prevented: 30,376 (in women) and 16,105 (in men)
- Life years gained: 6605 (in women) and 6144 (in men).
Sandmann (2016) Vitamin D and calcium food-fortification programme in the German female population
aged 65 years and older would lead to:
- Annual net cost savings of €315 million
- Annual total number of fractures prevented: 36,705
Hiligsmann (2017) Lifetime impact of recommended intake of dairy products in the general French
population for 1 year (2015):
- Total number of all fractures prevented: 64,392 (including 19,500 hip)
- 32,569 QALY gained and 29,169 life years gained.
DALY disability-adjusted life years, FR France, NL Netherlands, QALY quality-adjusted life years, SW
Switzerland
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In summary, all these studies reported a substantial public
health benefit of dairy products in terms of fractures prevented
as well as in life years, QALYor DALY gains. Direct compar-
ison of studies is difficult given the variety in methodology
and outcomes used. We could however mention that the ben-
efits in terms of fractures ranged from 132 hip fractures per
year in the Netherlands with additional dairy products to a
lifetime gained of 63,392 fractures in France for 1 year of
the recommended intake of dairy products.
Economic impact
Six studies assessed the cost-effectiveness of dairy products
(17–21, 23) (see Table 3).
The studies assessing the cost-effectiveness of calcium and
vitamin D supplementation without referring to dairy products
suggested that that the intervention is cost-effective in popu-
lations above 60 years with cost per QALY gained lower than
€45,000 (19, 20). The study of Hagen et al. (19) revealed
however that the potential cardiovascular effects of calcium
and vitamin D supplementation could alter this conclusion.
The studies assessing directly the cost per QALY gained of
dairy products suggested that the intervention is generally
cost-effective in the general population aged above 70 years
(21) or 80 years (17, 18) and from the age of 60 years in
population at increased risk of fractures. The study of
Sandmann et al. even suggested that the implementation of a
vitamin D and calcium food fortification programme is cost-
saving (i.e. intervention cost lower than saved costs resulting
from less fractures) in the German female population above
the age of 65 years.
Discussion
This systematic review identified seven studies that assessed the
public health and/or economic impact of vitamin D-fortified
dairy products (or of calcium and vitamin D supplementation).
Different strategies were used by the authors to model the pub-
lic health impact of dairy products making direct comparison
between studies difficult. The four studies assessing the public
health impact of dairy products revealed a substantial potential
gain of dairy products in terms of fracture prevented, life years
and DALYor QALY gained. By example, in France, the appro-
priate intake of dairy products in the year 2015 would lead to
the lifetime prevention of 64,392 fractures including 19,500 at
the hip. Given 65,697 hip fractures occurred in the year 2013 in
France (25), the potential benefits of dairy products are there-
fore substantial. Studies assessing the cost per QALY gained of
dairy products revealed that the use of dairy products is gener-
ally be cost-effective in the general population aged above
70 years and from the age of 60 years in populations at high
risk of fractures.
Our review therefore suggests that an adequate intake of
calcium and vitamin D supplementation by the administration
of dairy products could lead to a substantial decrease in the
burden of osteoporotic fractures (in terms of fractures
prevented, life years and QALY gained) and is cost-effective
in the general population above 70 years. This review could
provide relevant information for policy makers and clinicians
and help them to efficiently allocate resources. Our study rec-
ommends the implementation of programmes to increase the
intake of dairy products by policy makers. Clinicians should
also take actions and discuss with their patients the benefits of
calcium and vitamin D, to improve the consumption of dairy
products.
There are some potential limitations to our review. First, we
did not perform a complete systematic review following the
PRISMA statement. Only one reviewer searched the literature
and extracted data, and the search was also limited to one
database. However, backward and forward referencing was
conducted and the option Bsee all related^ from PubMed
was used for the identified article. Second, given the diversity
in study methodology and outcomes, we were not able to
perform a direct comparison between studies. Third, we did
not provide a quality assessment of the economic studies.
We also identified some limitations of current studies and
areas for further research. First, all studies assumed the effica-
cy of calcium and vitamin D derived from the literature, but
not specific to dairy products. There are currently no studies
directly estimating the effects of vitamin D-fortified dairy
products on fracture prevention. Future research should there-
fore collect longitudinal population data for documenting the
effects and net benefits of increasing dairy consumption on
bone health and on the related utilization of healthcare re-
sources (19). Second, studies would also be needed to collect
additional benefits/side effects of dairy products that could
potentially affect the economic benefits (19). Such effects
have been poorly investigated and thus often not included in
previous modelling studies. Third, further work needs to be
done on adherence to dairy products. Relatively few studies
have assessed the willingness of people to consume dairy
products. Although the study of Sandmann et al. (26) suggests
that a large majority of Germans would be willing to consume
vitamin D-fortified dairy products, further work needs to be
done about acceptance and adherence to fortified dairy prod-
ucts, and the potential effects on bone prevention. Finally, we
observed a large diversity in the methodology and outcomes
used to assess the effects of dairy products making comparison
between studies difficult. Further guidance/recommendations
needs to be done on how to model the public health and eco-
nomic impact of nutritional products.
In conclusion, this systematic review suggests that the use
of vitamin D-fortified dairy products could substantially re-
duce the burden of osteoporotic fractures and seem to be an
economically beneficial strategy.
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